| Literature DB >> 32917177 |
Dino Kröll1,2, Yves Michael Borbély3, Bastian Dislich4, Tobias Haltmeier3, Thomas Malinka5, Matthias Biebl5, Rupert Langer4, Daniel Candinas3, Christian Seiler3.
Abstract
BACKGROUND: Although considered complex and challenging, esophagectomy remains the best potentially curable treatment option for resectable esophageal and esophagogastric junction (AEG) carcinomas. The optimal surgical approach and technique as well as the extent of lymphadenectomy, particularly regarding quality of life and short- and long-term outcomes, are still a matter of debate. To lower perioperative morbidity, we combined the advantages of a one-cavity approach with extended lymph node dissection (usually achieved by only a two-cavity approach) and developed a modified single-cavity transhiatal approach for esophagectomy.Entities:
Keywords: En bloc lymphadenectomy; Esophageal cancer; Extended transhiatal esophagectomy; Long-term survival; Short-term outcome
Mesh:
Year: 2020 PMID: 32917177 PMCID: PMC7488573 DOI: 10.1186/s12893-020-00855-z
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Patient characteristics and clinical characteristics
| eTHE ( | |
|---|---|
| Age (years) | 67.0 (13.0) |
| Gender (male/female)a | 130/36 (78.3/21.7) |
| ASA score 2a | 53 (31.9) |
| ASA score 3a | 103 (62.0) |
| ASA score 4a | 10 (6.0) |
| Pulmonary diseasea | 49 (29.5) |
| Cardiovascular diseasea | 87 (52.4) |
| Neoadjuvant treatmenta | 144 (86.7) |
| cT-stage, n (%) | |
| cT1 | 14 (8.4) |
| cT2 | 44 (26.5) |
| cT3 | 106 (63.9) |
| cT4 | 2 (1.2) |
| cN-stage, n (%) | |
| cNo | 38 (22.9) |
| cN1 | 97 (58.4) |
| cN2 | 30 (18.1) |
| cN3 | 1 (0.6) |
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral mediastinal en bloc lymphadenectomy, BMI body mass index, ASA American Society of Anesthesiologists Physical Status Classification System
aValues are numbers (percentages)
Operative data and postoperative adverse outcomes after eTHE
| eTHE ( | |
|---|---|
| Operating time (min) | 380 (88) |
| Blood loss (ml) | 500 (238) |
| Clavien-Dindoa | |
| I | 32 (19.3) |
| II | 60 (36.1) |
| III | 19 (11.4) |
| IV | 12 (7.2) |
| V | 3 (1.8) |
| Vocal cord paresis/paralysisa | |
| Transient | 18 (10.8) |
| Permanent | 1 (0.6) |
| Anastomotic leaka | 19 (11.4) |
| Reoperation overalla | 9 (5.4) |
| Revision for leakagea | 3 (1.8) |
| SSIa | 16 (9.6) |
| Cardiovascular complicationsa | 51 (30.7) |
| Hospital-acquired pneumoniaa | 21 (12.7) |
| ARDSa | 4 (2.4) |
| In-hospital mortalitya | 2 (1.2) |
| 30-day mortalitya | 3 (1.8) |
| 90-day mortalitya | 7 (4.2) |
| Total hospital LOS | 17 (12.0) |
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral mediastinal en bloc lymphadenectomy, ARDS acute respiratory distress syndrome, SSI surgical site infection, LOS length of stay
a Values are numbers (percentages)
Histological features after eTHE
| eTHE ( | |
|---|---|
| Tumor localization, n (%) | |
| Upper third | 1 (0.6) |
| Middle third | 28 (16.9) |
| Distal third | 137 (82.5) |
| AEG Typ I | 101 (73.7) |
| AEG Typ II | 29 (21.2) |
| Tumor entity, n (%) | |
| Squamous carcinoma, n (%) | 46 (27.7) |
| Adenocarcinoma, n (%) | 114 (68.7) |
| Others | 6 (3.6) |
| (y) pT-Stagea | |
| ypT0 | 42 (25.3) |
| (y) pT1 | 46 (27.7) |
| (y)pT2 | 22 (13.3) |
| (y)pT3 | 56 (33.7) |
| N-Stagea | |
| pN0 | 111 (66.9) |
| pN1 | 32 (19.3) |
| pN2 | 16 (9.6) |
| pN3 | 7 (4.2) |
| TNM 8-Stagea | |
| I | 89 (53.6) |
| II | 19 (11.4) |
| IIIA | 15 (9.0) |
| IIIB | 30 (18.1) |
| IVA | 7 (4.2) |
| IVB | 6 (3.6) |
| RO resection | 161 (97.0) |
| No. of resected lymph nodes | 25 (17.0) |
| Complete response (Becker 1a)a | 49 (34.0) |
Values are medians (interquartile ranges) unless indicated otherwise
eTHE extended transhiatal esophageal resection with radical bilateral mediastinal en bloc lymphadenectomy
a Values are numbers (percentages)
Fig. 1Kaplan-Meier plots of the estimated overall survival for up to 5 years after cancer resection
Fig. 2Five-year survival stratified by pathological tumor stage. UICC, Union for International Cancer Control
Fig. 3Five-year survival stratified by Becker regression grade